C-CSF
Showing 1 - 25 of >10,000
Hematological Malignancy Trial in Ningbo (Etoposide, Cytarabine, PEG-rhG-CSF)
Recruiting
- Hematological Malignancy
- Etoposide
- +2 more
-
Ningbo, Zhejiang, ChinaThe Affiliated People's Hospital of Ningbo University.
Aug 18, 2022
Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)
Terminated
- Platinum Sensitive Ovarian Cancer
- Ovarian Cancer
- FRα peptide plus Adjuvant (GM-CSF)
- Adjuvant (GM-CSF) Alone
-
Birmingham, Alabama
- +17 more
Nov 21, 2022
Sickle Cell Anemia, Beta Thalassemia Trial run by the NHLBI (radiation, drug, biological)
Recruiting
- Sickle Cell Anemia
- Beta Thalassemia
- TBI
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Lymphoma, Multiple Myeloma Trial in China (Etoposide, Cytarabine, PEG-rhG-CSF)
Recruiting
- Lymphoma
- Multiple Myeloma
- Etoposide
- +2 more
-
Hangzhou, Zhejiang, China
- +6 more
Sep 7, 2022
Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)
Terminated
- Neuroblastoma
- antibody ch14.18
- +4 more
-
Cologne, GermanyUniversity of Cologne
Nov 3, 2022
Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)
Not yet recruiting
- Acute Myeloid Leukemia
- Myeloid Neoplasm
- Biospecimen Collection
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 5, 2023
Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level
Not yet recruiting
- Relapsed Adult AML
- Refractory AML
- Navitoclax Dose Level -1
- +10 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023
Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)
Active, not recruiting
- Acute Myeloid Leukemia
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 10, 2022
Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia
- Selinexor
- +5 more
-
Taiyuan, Shanxi, ChinaTao Wang
Feb 9, 2023
Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)
Not yet recruiting
- Leukemia, Acute Myeloid (AML)
- Clifutinib
- +5 more
- (no location specified)
Oct 16, 2022
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Leukemia Trial in Houston (Cyclophosphamide, Vincristine, Blinatumomab)
Not yet recruiting
- Leukemia
- Cyclophosphamide
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Dec 23, 2022
Acute Myelogenous Leukemia Trial in Australia, Canada, United States (Decitabine, Vorinostat, Filgrastim (G-CSF))
Completed
- Acute Myelogenous Leukemia
- Decitabine
- +4 more
-
Los Angeles, California
- +32 more
Jun 22, 2022
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma Trial run by the
Active, not recruiting
- AIDS-Related Burkitt Lymphoma
- +5 more
- Prednisone
- +7 more
-
Bethesda, MarylandNCI Lymphoid Malignancies Branch
Jul 31, 2022
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia Trial in Saint Louis (biological, drug, procedure)
Not yet recruiting
- Refractory Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Cytokine induced memory-like NK cells
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jun 30, 2022
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in
Terminated
- Philadelphia Chromosome Negative
- +2 more
- Blinatumomab
- +11 more
-
Houston, TexasM D Anderson Cancer Center
Nov 3, 2022
Healthy Volunteers Trial in New York (Clonidine Pill)
Withdrawn
- Healthy Volunteers
- Clonidine Pill
-
New York, New YorkWeill Cornell Medicine
Jul 14, 2021
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia Trial in Seattle (Cladribine, Cytarabine,
Recruiting
- Acute Biphenotypic Leukemia
- +11 more
- Cladribine
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 18, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +5 more
- Blinatumomab
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Feb 1, 2022
Rotated Teeth Trial in Bogotá (Er,Cr:YSGG laser-aided CSF, Conventional CSF)
Not yet recruiting
- Rotated Teeth
- Er,Cr:YSGG laser-aided CSF
- Conventional CSF
-
Bogotá, Bogotá D.c.,, ColombiaOrthodontic Clinic of Post-graduation Program UniCIEO
Feb 24, 2021
Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- DS-1594b
- +14 more
-
Houston, TexasM D Anderson Cancer Center
Oct 6, 2022
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome Trial in Minneapolis (Stem Cell Transplantation, IMD
Recruiting
- Mucopolysaccharidosis Disorders
- +28 more
- Stem Cell Transplantation
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Nov 1, 2022
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (drug, biological, other)
Completed
- Acute Leukemia of Ambiguous Lineage
- +2 more
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 23, 2022
Mantle Cell Lymphoma, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Houston (procedure, drug, biological)
Completed
- Mantle Cell Lymphoma
- +6 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Jan 18, 2022
Relapsed Solid Tumor, Refractory Solid Tumor Trial in Worldwide (Abemaciclib, Irinotecan, Temozolomide)
Recruiting
- Relapsed Solid Tumor
- Refractory Solid Tumor
- Abemaciclib
- +4 more
-
Phoenix, Arizona
- +28 more
Dec 7, 2022